Orthocell see 89% of patients return to work pain-free

Company News

by Rachael Jones

Regenerative medicine company Orthocell (ASX:OCC) reports the final results from patients who completed the CelGro® tendon regeneration clinical trial showing 89 per cent of patients return to work and recreation pain-free.

A review of patients who completed the trial confirmed all patients achieved a successful tendon repair with no revision surgeries reported.

CelGro® strengthens rotator cuff tendon repair in the shoulder.

No revision surgeries were reported at two years after CelGro® tendon regeneration surgery.

It's now shown to improve nerve, tendon and bone repair.

Shares in Orthocell (ASX:OCC) are trading 10.13 per cent higher at $0.43.

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?